Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care

Conclusions: Trials for adjuvant trastuzumab did not disambiguate between crossover (1) in the adjuvant setting or (2) at recurrence. Due to the low reported rate of crossover, it is questionable if participants received the standard of care.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Article Source Type: research